Alphyn Biologics, Inc., is a life science company creating a new class of drugs, Multi-Target Therapeutics™. These therapeutics are designed for more powerful and effective therapies utilizing patented multiple natural bioactive derivatives to target the most difficult, severe and prevalent skin diseases facing humankind. Lead bio derivative, AB-101’s is being applied for treatment of Atopic Dermatitis (or AD, also known as Eczema). AD is difficult to treat, can be very severe for many people and affects millions of people worldwide. Multi-Target Therapeutics is expected to provide AB-101 products with advantages in product efficacy and lower cost, faster FDA marketing authorization. The next key milestone for Alphyn’s AD product is the ongoing Phase 2 human clinical trial to treat AD in pediatric and adult patients.
Website: https://alphynbiologics.com/